Management of parkinson’s disease
Upcoming SlideShare
Loading in...5
×
 

Management of parkinson’s disease

on

  • 363 views

It contains the Management of Parkinson's disease and i think it will be most useful to medical students to refer.

It contains the Management of Parkinson's disease and i think it will be most useful to medical students to refer.

Statistics

Views

Total Views
363
Views on SlideShare
363
Embed Views
0

Actions

Likes
0
Downloads
15
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Management of parkinson’s disease Management of parkinson’s disease Presentation Transcript

  • MANAGEMENT OF PARKINSON’S DISEASE AAM. AMJATH MEDICINE 4TH BATCH FHCS-EUSL
  • Objectives • To Understand the Goals in Management of Parkinson’s Disease. • Describe the Pharmacological Intervention in Parkinson’s Disease. • Describe the Non-Pharmacological Intervention in Parkinson’s Disease. • Describe the Surgical Treatments in Parkinson’s Disease.
  • Goals of Management • Maintain the function • Avoid drug-induced complications • In the Tx of PD, Bradykinesia Tremor Rigidity Abnormal posture Respond Early in illness
  • • But… Cognitive symptoms Hypophonia Autonomic dysfunction Balance difficulties Respond Poorly
  • Pharmacological Management of Parkinson’s Disease. Drugs used in PD 1. Levodopa and Carbidopa 2. Anticholinergics(Trihexyphenidyl, Benztropine) 3. Amantadine 4. Catechol-O-methyltransferase inhibitors (COMT inhibitors 5. Monoamine oxidase type B (MAO-B) (Give temporary relief from the symptoms of the disorder, but not arrest or reverse the neuronal degeneration. )
  • Pharmacological Therapy in early PD • ‘Early disease’ refers to PD in people who have developed functional disability and require symptomatic therapy. • There is no single drug of choice in the initial pharmacotherapy of early PD.
  • Options for initial pharmacotherapy in early PD
  • • The dose of levodopa should be kept as low as possible to maintain good function in order to reduce the development of motor complications. • Beta blockers used in the symptomatic treatment of selected people with postural tremor in PD. • Anticholinergics may be used as a symptomatic treatment typically in young people with early PD and severe tremor
  • Pharmacological therapy in later PD • ‘Later disease’ refers to PD in people on levodopa who have developed motor complications. • There is no single drug of choice in the pharmacotherapy of later PD. • So, Adjuvant drugs are taken alongside with Levodopa for it. • Ex: COMT inhibitors, MAO-B inhibitors, Dopamine agonist, Amantadine… etc.
  • Options for adjuvant pharmacotherapy in later PD
  • • Modified-release levodopa preparations may be used to reduce motor complications in people with later PD, but should not be drugs of first choice. • MAO-B & COMT inhibitors may be used to reduce motor fluctuations and Amantadine may be used to reduce dyskinesia in people with later PD.
  • Non-Pharmacological Management of Parkinson’s Disease. • It includes,  Rehabilitation. Diet. Physiotherapy Speech & Language therapy Occupational therapy
  • Rehabilitation • Physiotherapy It helps to improve the, a. Mobility. b. Flexibility. c. Strength. d. Gait speed. e. Aerobic capacity. f. Quality of life.
  • • Speech and language therapy  Particular consideration should be given to : a. improvement of vocal loudness and pitch range. b. Ensuring an effective means of communication is maintained throughout the course of the disease. c. review and management to support safety and efficiency of swallowing and to minimise the risk of aspiration.
  • • Occupational therapy  Particular consideration should be given to : a. maintenance of work and family roles, home care and leisure activities. b. improvement and maintenance of transfers and mobility. c. improvement of personal self-care activities, such as eating, drinking, washing and dressing.
  • Diet • Diet should include high fibre foods and plenty of water. • When levodopa is introduced excessive proteins are discouraged due to competition between them to cross the BBB and intestine. • So, To minimize interaction with proteins, levodopa is recommended to be taken 30 minutes before meals.
  • Surgical Treatment • In refractory cases, Surgical Tx is considered. • Deep-brain stimulation (DBS) is presently the most used Sx method. • Here Subthalamic nucleus(STN) or Globus pallidus interna (GPi) is stimulated. • I˚ : Patients who suffer disability resulting from levodopa-induced motor complications. • CI : a) Cognitive Impairment. b) Major Psy.illnesses c) Substantial medical comorbidities d) Advanced age